Let's check in on the other 3CL protease inhibitor
Post# of 1418
(Total Views: 254)
Posted On: 04/23/2022 8:01:43 PM
Let's check in on the other 3CL protease inhibitor company
Enanta Pharmaceuticals Inc
Mkt cap: $1.53B
Net loss for the three months ended December 31, 2021 was $30.1 million but they do have one drug in market that they get royalties from. Some Liver thingie Protease Inhibitor
"Currently, EDP-235 is in a first-in-human Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of oral EDP-235 in single ascending doses (SAD), including a two-part food effect cohort, and multiple ascending doses (MAD), compared to placebo in healthy volunteers"
I tell you folks it's harder than it looks...
Enanta Pharmaceuticals Inc
Mkt cap: $1.53B
Net loss for the three months ended December 31, 2021 was $30.1 million but they do have one drug in market that they get royalties from. Some Liver thingie Protease Inhibitor
"Currently, EDP-235 is in a first-in-human Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of oral EDP-235 in single ascending doses (SAD), including a two-part food effect cohort, and multiple ascending doses (MAD), compared to placebo in healthy volunteers"
I tell you folks it's harder than it looks...
(1)
(0)